Consistency of treatment effect across the range of baseline HbA1c in patients with type 2 diabetes mellitus (T2DM) treated with once-weekly dulaglutide or comparators in AWARD-1,…

Objective: To characterise the relative effects of once-weekly dulaglutide (DU) and active comparators on change in HbA1c across the continuous range of baseline HbA1c values. Methods: This exploratory post-hoc analysis included adult patients with T2DM randomised to DU1.5 mg, DU0.75 mg or exenatide 10mcg twice daily (AWARD-1; N = 835), DU1.5 mg, DU0.75 mg or sitagliptin 100 mg once daily (AWARD-5; N = 921), or DU1.5 mg or liraglutide 1.8 mg once daily (AWARD-6; N = 599), all with metformin (AWARD-5, -6) or metformin+pioglitazone (AWARD-1); placebo populations not included. Changes in HbA1c were evaluated at pri…